Details of the Drug | DrugMAP

General Information of Drug (ID: DMFSHI6)

Drug Name

177-Lu-edotreotide

Indication

Disease Entry	ICD 11	Status	REF
Neuroendocrine cancer	2B72.1	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Somatostatin analogue

Cross-matching ID

TTD ID: D29XIA

References

1	ClinicalTrials.gov (NCT04919226) A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin. U.S.National Institutes of Health.